A Phase 3 interventional study of Recombinant von Willebrand Factor (rVWF) in Von Willebrand Disease, sponsored by Baxalta now part of Shire. Completed at 34 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in von Willebrand Diseases by Takeda — 3 open to participants now, 3 under way, 2 of them phase 3. von Willebrand Diseases · Takeda.
Among the 13 studies in von Willebrand Diseases by Takeda, this one is the only one that started in 2015, is one of 7 in phase 3, and was the 3rd registered.
96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.
Browse von Willebrand Diseases studies →3 of the 13 studies in von Willebrand Diseases by Takeda are open now, in 7 countries. Recruiting first, the newest first:
Takeda · Sites in Japan
Ages up to 17
Takeda · Sites in China
Ages 18+
Takeda · Sites in United States, France, Ireland and 3 more countries
Ages up to 17
By country, each count listing its studies:
Of the 23 von Willebrand Diseases studies recruiting now, 15 (65%) set no upper age limit and 8 (35%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2015.
This study's enrollment of 24 is close to the median of 25 across 41 interventional studies indexed under von Willebrand Diseases.
Median enrollment 31 across the 8 interventional studies, 24 across the 4 observational. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
1 of the studies in von Willebrand Diseases by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129343Phase 3TakedaA Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) | 2027-11-25 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in von Willebrand Diseases by Takeda, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in adult patients with hereditary severe von Willebrand disease (VWD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of severe von Willebrand disease (VWD) as listed below and elective surgical procedure planned
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
Biological: Recombinant von Willebrand Factor (rVWF)
rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
Overall Hemostatic Efficacy as Assessed by the Investigator (Hemophilia Physician)
Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intra-, and postoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intra-, and postoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intra-, and postoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.
Time frame: 24 hours after last peri-operative infusion or at completion of Day 14 (± 2 days) visit, whichever occurs earlier
Intraoperative Actual Versus Predicted Blood Loss as Assessed by the Operating Surgeon
The predicted blood loss will be estimated preoperatively by the operating surgeon based on a hemostatically normal individual of the same sex, age, stature and co-morbidities as the participant. The actual blood loss will be assessed consisting of the estimated blood loss, including into swabs, towels and suction during the procedure, per the anesthesiologist's record.
Time frame: Day 0 (at completion of surgery)
Intraoperative Actual Blood Loss Relative to Predicted Blood Loss
Actual blood loss relative to predicted blood loss will be calculated as \[Actual Blood loss (mL)\] divided by \[Predicted Blood Loss (mL) multiplied by 100.
Time frame: Day 0 (at completion of surgery)
Intraoperative Actual Versus Predicted Blood Loss Score as Assessed by the Operating Surgeon
Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative blood loss was less than or equal to the maximum blood loss expected for the type of procedure performed in a hemostatically normal subject (≤ 100%). Good: Intraoperative blood loss was up to 50% more than the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (101-150%) Moderate: Intraoperative blood loss was more than 50% of the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (\>150%). None: Uncontrolled hemorrhage that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of clotting factor replacement regimen.
Time frame: Day 0 (at completion of surgery)
Intraoperative Hemostatic Efficacy Score as Assessed by the Operating Surgeon
Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intraoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intraoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.
Time frame: Day 0 (at completion of surgery)
Daily Intra- and Postoperative Weight-adjusted Dose of rVWF With or Without ADVATE
Time frame: Daily, from day of surgery through postoperative Day 14 (± 2 days)
Occurrence of Adverse Events
Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated.
Time frame: From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)
Occurrence of Thrombotic Events
Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for thrombotic events.
Time frame: From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)
Occurrence of Severe Allergic Reactions (eg, Anaphylaxis)
Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for severe allergic reactions.
Time frame: From first infusion of investigational product through study completion (ie, 14 (± 2) days post surgery)
Number of Participants Who Developed Inhibitory and Total Binding Antibodies to Von Willebrand Factor (VWF) and Inhibitory Antibodies to Factor VIII (FVIII)
Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.
Time frame: Testing occurred throughout the study at screening, prior PK infusion, pre-surgery, post surgery in case of excessive bleeding or unexplained bleeding, at postoperative day 7 and at study completion visit (ie. 14 (± 2) days post surgery).
Number of Participants Who Developed Antibodies to Chinese Hamster Ovary (CHO) Proteins, Mouse Immunoglobulin G (IgG) or Recombinant Furin (rFurin)
Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.
Time frame: Testing occurred throughout the study at screening, prior PK infusion, pre-surgery, post surgery in case of excessive bleeding or unexplained bleeding, at postoperative day 7 and at study completion visit (ie. 14 (± 2) days post surgery).
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Post-infusion (AUC 0-72 h/Dose)
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from 0 to 72 hours post-infusion will be computed using the linear trapezoidal rule. For the calculation of AUC(0-72h) the levels at 72 hours will be linearly interpolated/extrapolated from the 2 nearest sampling time points. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)
Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC 0-∞ /Dose)
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from time 0 to infinity and the area under the first moment curve from time 0 to infinity will be calculated as the sum of AUC or AUMC from time 0 to the time of last quantifiable concentration plus a tail area correction calculated as Ct/λz and Ct/λz(t+1/λz), respectively, where Ct is the last quantifiable concentration, t is the time of last quantifiable concentration and λz is the terminal or disposition rate constant. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)
Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Pharmacokinetics: Mean Residence Time (MRT)
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Mean residence time will be calculated as area under the first moment curve from time 0 to infinity divided by the area under the curve time 0 to infinity minus T/2 where T is the duration of the infusion. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Pharmacokinetics: Clearance (CL)
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Clearance will be calculated as dose (IU/kg) divided by the area under the curve time 0 to infinity. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Pharmacokinetics: Incremental Recovery (IR)
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Incremental recovery will be calculated as (Cmax minus Cpreinfusion) divided by the dose (IU/kg) where kg refers to the body weight at the time of dosing and Cmax is the observed maximum concentration before correction for pre-infusion values. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Pharmacokinetics: Elimination Phase Half-life (T1/2)
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Terminal or disposition half-life (T1/2) will be calculated as ln2/λz where λz is the terminal elimination rate constant as calculated in WinNonlin NCA using at least three quantifiable concentrations. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Pharmacokinetics: Volume of Distribution at Steady State (Vss)
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Vss will be calculated as the clearance multiplied with the mean residence time. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
Time frame: PK measurements were done within 30 minutes pre-infusion, and post infusion at 30 (± 5) minutes, 60 (± 5) minutes, 6 (± 1) hours, 12 (± 1) hours, 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Enrollment was conducted at 14 study sites in 10 countries (USA, Australia, Taiwan, Germany, Russia, Spain, Ukraine, United Kingdom, Italy, Turkey).
| Milestone | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Started | 15 |
| Completed | 14 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intra-, and postoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intra-, and postoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intra-, and postoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.
| Participants | Recombinant Von Willebrand Factor (rVWF) | Minor Surgery | Major Surgery | Oral Surgery | Von Willebrand Disease Type 1 | Von Willebrand Disease Type 2A | Von Willebrand Disease Type 2B | Von Willebrand Disease Type 2M | Von Willebrand Disease Type 3 |
|---|---|---|---|---|---|---|---|---|---|
| Excellent | 11 | 4 | 7 | 0 | 2 | 1 | 1 | 0 | 7 |
| Good | 4 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 |
| Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| None | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The predicted blood loss will be estimated preoperatively by the operating surgeon based on a hemostatically normal individual of the same sex, age, stature and co-morbidities as the participant. The actual blood loss will be assessed consisting of the estimated blood loss, including into swabs, towels and suction during the procedure, per the anesthesiologist's record.
| mL | Recombinant Von Willebrand Factor (rVWF) | Minor Surgery | Major Surgery | Oral Surgery | Von Willebrand Disease Type 1 | Von Willebrand Disease Type 2A | Von Willebrand Disease Type 2B | Von Willebrand Disease Type 2M | Von Willebrand Disease Type 3 |
|---|---|---|---|---|---|---|---|---|---|
| Actual blood loss | 94.3 ± 177.88 | 0.0 ± 0.00 | 127.0 ± 209.27 | 145.0 ± NA | 115.0 ± 103.32 | 42.5 ± 53.03 | 50.0 ± NA | 50.0 ± NA | 110.6 ± 240.87 |
| Predicted blood loss | 106.1 ± 161.82 | 2.5 ± 5.00 | 152.8 ± 186.33 | 100.0 ± NA | 100.0 ± 100.00 | 10.0 ± NA | 50.0 ± NA | 50.0 ± NA | 134.4 ± 206.46 |
Actual blood loss relative to predicted blood loss will be calculated as \[Actual Blood loss (mL)\] divided by \[Predicted Blood Loss (mL) multiplied by 100.
| Percent | Recombinant Von Willebrand Factor (rVWF) | Minor Surgery | Major Surgery | Oral Surgery | Von Willebrand Disease Type 1 | Von Willebrand Disease Type 2A | Von Willebrand Disease Type 2B | Von Willebrand Disease Type 2M | Von Willebrand Disease Type 3 |
|---|---|---|---|---|---|---|---|---|---|
| Intraoperative Actual Blood Loss Relative to Predicted Blood Loss | 69.6 ± 44.77 | 0.0 ± NA | 68.9 ± 34.48 | 145.0 ± NA | 122.5 ± 31.82 | 50.0 ± NA | 100.0 ± NA | 100.0 ± NA | 45.0 ± 38.92 |
Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative blood loss was less than or equal to the maximum blood loss expected for the type of procedure performed in a hemostatically normal subject (≤ 100%). Good: Intraoperative blood loss was up to 50% more than the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (101-150%) Moderate: Intraoperative blood loss was more than 50% of the maximum expected blood loss for the type of procedure performed in a hemostatically normal subject (\>150%). None: Uncontrolled hemorrhage that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of clotting factor replacement regimen.
| Participants | Recombinant Von Willebrand Factor (rVWF) | Minor Surgery | Major Surgery | Oral Surgery | Von Willebrand Disease Type 1 | Von Willebrand Disease Type 2A | Von Willebrand Disease Type 2B | Von Willebrand Disease Type 2M | Von Willebrand Disease Type 3 |
|---|---|---|---|---|---|---|---|---|---|
| Excellent | 13 | 4 | 8 | 1 | 3 | 1 | 1 | 1 | 7 |
| Good | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 |
| Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| None | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none. Excellent: Intraoperative hemostasis achieved with rVWF with our without ADVATE was as good or better than that expected for the type of surgical procedure performed in a hemostatically normal subject. Good: Intraoperative hemostasis achieved with rVWF with or without ADVATE was probably as good as that expected for the type of surgical procedure performed in a hemostatically normal subject. Moderate: Intraoperative hemostasis with rVWF with or without ADVATE was clearly less than optimal for the type of procedure performed but was maintained without the need to change the rVWF concentrate. None: Participant experienced uncontrolled bleeding that was the result of inadequate therapeutic response despite proper dosing, necessitating a change of rVWF concentrate.
| Participants | Recombinant Von Willebrand Factor (rVWF) | Minor Surgery | Major Surgery | Oral Surgery | Von Willebrand Disease Type 1 | Von Willebrand Disease Type 2A | Von Willebrand Disease Type 2B | Von Willebrand Disease Type 2M | Von Willebrand Disease Type 3 |
|---|---|---|---|---|---|---|---|---|---|
| Excellent | 13 | 4 | 8 | 1 | 3 | 1 | 1 | 1 | 7 |
| Good | 2 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 1 |
| Moderate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| None | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| IU/kg | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| intraoperative | 18.1 (18.1 to 18.1) |
| postoperative day 1 | 23.5 (16.9 to 47.2) |
| postoperative day 2 | 42.3 (23.2 to 50.6) |
| postoperative day 3 | 28.6 (20.6 to 48.9) |
| postoperative day 4 | 33.9 (23.2 to 44.3) |
| postoperative day 5 | 31.5 (18.8 to 47.2) |
| postoperative day 6 | 23.2 (18.8 to 23.6) |
| postoperative day 7 | 23.8 (23.6 to 50.8) |
| postoperative day 8 | 33.9 (23.6 to 53.6) |
| postoperative day 9 | 23.6 (16.3 to 53.6) |
| postoperative day 10 | 23.6 (16.3 to 34.8) |
| postoperative day 11 | 23.6 (16.3 to 53.6) |
| postoperative day 12 | 29.3 (20.1 to 44.2) |
| postoperative day 13 | 16.3 (16.3 to 16.3) |
| postoperative day 14 | 25.5 (16.3 to 34.8) |
| postoperative day 15 | 16.3 (16.3 to 16.3) |
Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated.
| Adverse Events | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Treatment emergent Adverse Events (TEAEs) | 12 |
| Severe TEAEs | 1 |
| TEAEs related to rVWF | 0 |
| TEAEs related to ADVATE | 0 |
| TEAEs related to both rVWF and ADVATE | 0 |
| Treatment emergent Serious Adverse Events (TESAEs) | 2 |
| TESAEs related to rVWF | 0 |
| TESAEs related to ADVATE | 0 |
| TESAEs related to both rVWF and ADVATE | 0 |
| TEAEs leading to discontinuation of rVWF | 0 |
| TEAEs leading to discontinuation of ADVATE | 0 |
| TEAEs leading to discontinuation of study | 0 |
| TEAEs leading to death | 0 |
| TEAEs related to study procedure | 0 |
| TESAEs related to study procedure | 0 |
Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for thrombotic events.
| Adverse Events | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Thrombotic TEAEs | 2 |
| Thrombotic TESAEs | 1 |
Treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs) will be evaluated for severe allergic reactions.
| Adverse Events | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Severe allergic reaction TEAEs | 0 |
| Severe allergic reaction TESAEs | 0 |
Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.
| Participants | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Development of inhibitory antibodies to VWF | 0 |
| Development of total binding antibodies to VWF | 1 |
| Development of inhibitory antibodies to FVIII | 0 |
Participants were treated with recombinant van Willebrand Factor (rVWF) with or without ADVATE.
| Participants | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Number of Participants Who Developed Antibodies to Chinese Hamster Ovary (CHO) Proteins, Mouse Immunoglobulin G (IgG) or Recombinant Furin (rFurin) | 0 |
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from 0 to 72 hours post-infusion will be computed using the linear trapezoidal rule. For the calculation of AUC(0-72h) the levels at 72 hours will be linearly interpolated/extrapolated from the 2 nearest sampling time points. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)
| hours*IU/dL | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| VWF:RCo | 31.91 ± 37.5 |
| VWF:Ag | 57.08 ± 25.6 |
| VWF:CB | 63.91 ± 29.4 |
| VWF:Ac | 54.61 ± 28.1 |
| FVIII:C | 67.49 ± 31.1 |
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. The area under the plasma concentration/time curve from time 0 to infinity and the area under the first moment curve from time 0 to infinity will be calculated as the sum of AUC or AUMC from time 0 to the time of last quantifiable concentration plus a tail area correction calculated as Ct/λz and Ct/λz(t+1/λz), respectively, where Ct is the last quantifiable concentration, t is the time of last quantifiable concentration and λz is the terminal or disposition rate constant. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac), FVIII Coagulation Activity (FVIII:C)
| hours*IU/dL | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| VWF:RCo | 34.43 ± 43.3 |
| VWF:Ag | 68.87 ± 31.5 |
| VWF:CB | 71.82 ± 34.1 |
| VWF:Ac | 61.90 ± 32.2 |
| FVIII:C | 75.00 ± 30.9 |
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Mean residence time will be calculated as area under the first moment curve from time 0 to infinity divided by the area under the curve time 0 to infinity minus T/2 where T is the duration of the infusion. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
| hours | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| VWF:RCo | 22.69 ± 41.3 |
| VWF:Ag | 37.92 ± 28.4 |
| VWF:CB | 29.35 ± 31.1 |
| VWF:Ac | 29.75 ± 28.6 |
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Clearance will be calculated as dose (IU/kg) divided by the area under the curve time 0 to infinity. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
| dL/hour/kg | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| VWF:RCo | 0.02904 ± 43.3 |
| VWF:Ag | 0.01452 ± 31.5 |
| VWF:CB | 0.01392 ± 34.1 |
| VWF:Ac | 0.01616 ± 32.2 |
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Incremental recovery will be calculated as (Cmax minus Cpreinfusion) divided by the dose (IU/kg) where kg refers to the body weight at the time of dosing and Cmax is the observed maximum concentration before correction for pre-infusion values. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
| IU/dL | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| VWF:RCo | 1.961 ± 0.45445 |
| VWF:Ag | 1.991 ± 0.38395 |
| VWF:CB | 2.780 ± 0.56640 |
| VWF:Ac | 2.635 ± 0.38050 |
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Terminal or disposition half-life (T1/2) will be calculated as ln2/λz where λz is the terminal elimination rate constant as calculated in WinNonlin NCA using at least three quantifiable concentrations. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
| hours | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| VWF:RCo | 16.52 ± 42.7 |
| VWF:Ag | 26.88 ± 26.5 |
| VWF:CB | 21.07 ± 33.2 |
| VWF:Ac | 22.19 ± 28.5 |
This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery. Vss will be calculated as the clearance multiplied with the mean residence time. PK analysis was performed for the following analytes: VWF Ristocetin Cofactor Activity (VWF:RCo), VWF Antigen Activity (VWF:Ag), VWF Collagen Binding Activity (VWF:CB), VWF Activity Measured INNOVANCE VWF Ac Assay (VWF:Ac)
| dL/kg | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| VWF:RCo | 0.6591 ± 28.8 |
| VWF:Ag | 0.5506 ± 18.4 |
| VWF:CB | 0.4086 ± 24.0 |
| VWF:Ac | 0.4806 ± 21.5 |
Collected over Throughout the study period (from the first exposure to investigational product until study completion or discontinuation date). Total study duration: 1 year and 3 months. Per participant: up to 58 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Recombinant Von Willebrand Factor (rVWF) | 0/15 (0%) | 2/15 (13.3%) | 6/15 (40%) |
| Event | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| DiverticulitisInfections and infestations | 1/15 |
| Deep vein thrombosisVascular disorders | 1/15 |
| Event | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| AcneSkin and subcutaneous tissue disorders | 1/15 |
| Dry skinSkin and subcutaneous tissue disorders | 1/15 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/15 |
| Peripheral swellingGeneral disorders | 1/15 |
| NasopharyngitisInfections and infestations | 1/15 |
| Joint swellingMusculoskeletal and connective tissue disorders | 1/15 |
| DizzinessNervous system disorders | 1/15 |
| HeadacheNervous system disorders | 1/15 |
| Pelvic painReproductive system and breast disorders | 1/15 |
| Deep vein thrombosisVascular disorders | 1/15 |
| Age, Continuous(Years) | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Median | 40.0 (20.0 to 70.0) |
| Sex: Female, Male(Participants) | Recombinant Von Willebrand Factor (rVWF) |
|---|---|
| Female | 8 |
| Male | 7 |
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Apr 2015 to primary completion in Jul 2016, 15 months.
Results were first posted in Aug 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonicog alfa